Table 3

Prevalence of Individual FCI Comorbidities by Data Collection Method (n = 421)
FCI Comorbidity, n (%) Prospective: Admission Records Retrospective: Discharge Summaries p-value*
Arthritis (rheumatoid and osteoarthritis) 4 (1) 23 (5) <0.01
Osteoporosis 4 (1) 10 (2) 0.03
Asthma 16 (4) 28 (7) <0.01
COPD, emphysema, or ARDS 21 (5) 56 (13) <0.01
Angina 1 (1) 1 (1) 1.00
Congestive heart failure (or heart disease) 80 (19) 84 (20) 0.07
Myocardial infarction 24 (6) 13 (3) 0.03
Neurological disease (e.g., MS or Parkinson’s) 7 (2) 55 (13) <0.01
Stroke or TIA 34 (8) 25 (6) 0.32
Peripheral vascular disease 13 (3) 25 (6) <0.01
Diabetes type I or II 105 (25) 81 (19) 0.74
Upper GI disease (e.g., ulcer, hernia, reflux) 26 (6) 77 (18) <0.01
Depression 39 (9) 62 (15) <0.01
Anxiety or panic disorders 7 (2) 22 (5) <0.01
Visual impairment (e.g., cataracts, glaucoma) 2 (1) 9 (2) <0.01
Hearing impairment (e.g., hard of hearing with aids) 1 (1) 1 (1) 0.32
Degenerative disc disease (e.g., spinal stenosis) 8 (2) 14 (3) 0.01
FCI Score, median (IQR)** 1 (0–2) 2 (1–3) <0.01

Abbreviations: ARDS, acute respiratory distress syndrome; COPD, chronic obstructive pulmonary disease; GI, gastrointestinal; MS, multiple sclerosis; TIA, transient ischemic attack.

* Comparison made using McNemar’s test.

** For the FCI score, comparison made using Wilcoxon signed-rank test.

Fan et al.

Fan et al. BMC Anesthesiology 2012 12:21   doi:10.1186/1471-2253-12-21

Open Data